Blood pressure reduction and RAAS inhibition in diabetic kidney disease : therapeutic potentials and limitations
Diabetic kidney disease (DKD) affects approximately one-third of patients with diabetes and taking into consideration the high cardiovascular risk burden associated to this condition a multifactorial therapeutic approach is traditionally recommended, in which glucose and blood pressure control play a central role. The inhibition of renin-angiotensin-aldosterone RAAS system represent traditionally the cornerstone of DKD. Clinical outcome trials have demonstrated clinical significant benefit in slowing nephropathy progression mainly in the presence of albuminuria. Thus, international guidelines mandate their use in such patients. Given the central role of RAAS activity in the pathogenesis and progression of renal and cardiovascular damage, a more profound inhibition of the system by the use of multiple agents has been proposed in the past, especially in the presence of proteinuria, however clinical trials have failed to confirm the usefulness of this therapeutic approach. Furthermore, whether strict blood pressure control and pharmacologic RAAS inhibition entails a favorable renal outcome in non-albuminuric patients is at present unclear. This aspect is becoming an important issue in the management of DKD since nonalbuminuric DKD is currently the prevailing presenting phenotype. For these reasons it would be advisable that blood pressure management should be tailored in each subject on the basis of the renal phenotype as well as related comorbidities. This article reviews the current literature and discusses potentials and limitation of targeting the RAAS in order to provide the greatest renal protection in DKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of nephrology - 33(2020), 5 vom: 17. Okt., Seite 949-963 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leoncini, Giovanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albuminuria |
|---|
| Anmerkungen: |
Date Completed 18.08.2021 Date Revised 12.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40620-020-00803-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312578121 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312578121 | ||
| 003 | DE-627 | ||
| 005 | 20231225144718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40620-020-00803-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM312578121 | ||
| 035 | |a (NLM)32681470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leoncini, Giovanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blood pressure reduction and RAAS inhibition in diabetic kidney disease |b therapeutic potentials and limitations |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2021 | ||
| 500 | |a Date Revised 12.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Diabetic kidney disease (DKD) affects approximately one-third of patients with diabetes and taking into consideration the high cardiovascular risk burden associated to this condition a multifactorial therapeutic approach is traditionally recommended, in which glucose and blood pressure control play a central role. The inhibition of renin-angiotensin-aldosterone RAAS system represent traditionally the cornerstone of DKD. Clinical outcome trials have demonstrated clinical significant benefit in slowing nephropathy progression mainly in the presence of albuminuria. Thus, international guidelines mandate their use in such patients. Given the central role of RAAS activity in the pathogenesis and progression of renal and cardiovascular damage, a more profound inhibition of the system by the use of multiple agents has been proposed in the past, especially in the presence of proteinuria, however clinical trials have failed to confirm the usefulness of this therapeutic approach. Furthermore, whether strict blood pressure control and pharmacologic RAAS inhibition entails a favorable renal outcome in non-albuminuric patients is at present unclear. This aspect is becoming an important issue in the management of DKD since nonalbuminuric DKD is currently the prevailing presenting phenotype. For these reasons it would be advisable that blood pressure management should be tailored in each subject on the basis of the renal phenotype as well as related comorbidities. This article reviews the current literature and discusses potentials and limitation of targeting the RAAS in order to provide the greatest renal protection in DKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Albuminuria | |
| 650 | 4 | |a Blood pressure | |
| 650 | 4 | |a Diabetic kidney disease | |
| 650 | 4 | |a RAAS inhibition | |
| 650 | 4 | |a Renal progression | |
| 700 | 1 | |a Viazzi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a De Cosmo, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Fioretto, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Pontremoli, Roberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nephrology |d 1995 |g 33(2020), 5 vom: 17. Okt., Seite 949-963 |w (DE-627)NLM08977650X |x 1724-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2020 |g number:5 |g day:17 |g month:10 |g pages:949-963 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40620-020-00803-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2020 |e 5 |b 17 |c 10 |h 949-963 | ||